Results 11 to 20 of about 27,849,568 (325)

Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study. [PDF]

Microorganisms, 2023
Background: Increasing evidence suggests the beneficial effects of probiotics in irritable bowel syndrome (IBS), but little is known about how they can impact the gut microbiota. Our objective was to evaluate the effects of a multistrain probiotic on IBS
Marchix J, Quénéhervé L, Bordron P, Aubert P, Durand T, Oullier T, Blondeau C, Ait Abdellah S, Bruley des Varannes S, Chaffron S, Coron E, Neunlist M.   +11 more
europepmc   +2 more sources

Distinct psychophysiological biomarkers and risk stratification models for irritable bowel syndrome with constipation (IBS-C) and diarrhea (IBS-D) [PDF]

Scientific Reports
Irritable bowel syndrome (IBS) is a prevalent disorder of gut-brain interaction (DGBI) with a complex, multifactorial pathogenesis. Emerging evidence underscores the significant role of psychosocial factors; however, comprehensive models integrating ...
Xiaoqing Chen, Yujing Wang, Yanhong Hou, Lin Zhang, Kai Wu, Chao Wang   +5 more
doaj   +2 more sources

Vitamin D Deficiency (VDD) and Benefits of Supplementation in Veterans with IBS-D. [PDF]

Diagnostics (Basel), 2023
Many veterans deployed to Gulf War areas suffer from persistent chronic diarrhea that is disabling and affects their quality of life. The causes for this condition have eluded investigators until recently and recent literature has shed light on the effect of vitamin D on the brain–gut axis. This study focused on determining clinical causes contributing
Kesavan C, Das A, Goyal P, Jackson CS, Strong DD, Strong RM.   +5 more
europepmc   +4 more sources

Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D

Gut microbes, 2022
Fecal microbiota transplantation (FMT) is an attractive strategy to correct microbial dysbiosis in diarrhea-predominant irritable bowel syndrome (IBS-D).
Prashant Singh, E. Alm, J. Kelley, Vivian Cheng, Mark Smith, Z. Kassam, Judy W. Nee, J. Iturrino, A. Lembo   +8 more
semanticscholar   +2 more sources

The Neutrophil-to-Albumin Ratio (NAR): A Novel Index in Relation to Clinical Symptoms, Quality of Life, and Psychological Status in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). [PDF]

J Inflamm Res
Introduction Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by chronic abdominal pain and alterations in bowel habits.
Huang X, Li A, Long P, Liu Y, Zhou Z, Pan Y.   +5 more
europepmc   +2 more sources

Serum zonulin is elevated in IBS and correlates with stool frequency in IBS‐D [PDF]

United European Gastroenterology Journal, 2019
Background Studies have shown increased intestinal permeability in irritable bowel syndrome. Validating serum biomarkers for altered intestinal permeability in irritable bowel syndrome will facilitate research and pathophysiology‐based therapy. Objective
Prashant Singh, Jocelyn Silvester, Xinhua Chen, Hua Xu, Veer Sawhney, Vikram Rangan, Johanna Iturrino, Judy Nee, Donald R. Duerksen, Anthony Lembo   +9 more
openaire   +3 more sources

The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D) [PDF]

Therapeutic Advances in Gastroenterology, 2015
Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder. Serotonin (5-HT) is known to play a physiological and pathophysiological role in the regulation of gastrointestinal function. In experimental studies, 5-HT3 receptor antagonists have been reported to slow colon transit, to blunt gastrocolonic reflex, and to reduce rectal ...
Yang Won Min, Poong-Lyul Rhee
openaire   +4 more sources

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D) [PDF]

Gut, 2015
Introduction Immune activation has been reported in the mucosa of IBS patients with diarrhoea (IBS-D), and some small studies have suggested that mesalazine may reduce symptoms.
C. Lam, Wei Tan, Matthew P. Leighton, M. Hastings, M. Lingaya, Y. Falcone, Xiaoying Zhou, Luting Xu, P. Whorwell, A. Walls, A. Zaitoun, A. Montgomery, R. Spiller   +12 more
semanticscholar   +2 more sources

TREATMENT OF IBS-D CASES THROUGH RIFAXIMIN

, 2019
Objectives: Our aim was to observe the outcome of Rifaximin for the cases having IBS-D. Study design: A descriptive case control study. Place and Duration: We conducted this study for a time duration of 12 months starting from the month of January, 2018 to month of December, 2018 at medical OPD of Services Hospital in Lahore.
Dr. Saba Shabir, Dr. Qamar Gul, Dr. Jawariya Zia
openaire   +3 more sources

Clinical correlation between serum vitamin D level and Irritable Bowel Syndrome [PDF]

Minia Journal of Medical Research, 2022
Background: Irritable bowel syndrome (IBS) is a common functional bowel disorder characterized by recurrent abdominal pain or discomfort associated with altered bowel habit.
Amr Elsayed, Zaki Zaki, Inas Kamal Mohamed, Sara Ali   +3 more
doaj   +1 more source